Assembly Biosciences
Carmel
About Assembly Biosciences
Assembly Biosciences is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $542.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: nasdaq:ASMB
- Website: assemblybio.com
- Phone: +1 646-706-5208
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/assembly-biosciences-81064 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.